Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors

다국어 초록 (Multilingual Abstract)

Clinical and preclinical studies have indicatedthat chronic methamphetamine (MA) use is associated withextensive neurodegeneration, psychosis, and cognitiveimpairment. Evidence from animal models has suggested aconsiderable role of excess dopamine or glutamate,oxidative stress, neuroinflammation, and apoptosis in MAinducedneurotoxicity, and that protein kinase Cd mightmediate the interaction among these factors. In addition,the relatively long-lasting and recurrent nature of MApsychosis has been reproduced in animals treated withvarious dosing regimens of MA, which have shownbehavioral sensitization, sociability deficits, and impairedprepulse inhibition. Genetic predisposition as well asdopaminergic and glutamatergic alterations might beimportant in the development of MA psychosis. Neuroimagingstudies have identified functional andmorphological changes related to the cognitive dysfunctionshown in chronic MA users. Failure in the task-evokedphosphorylation of extracellular signal-related kinaselikely underlies MA-induced memory impairment. Recentprogress has suggested certain roles of oxidative stress andneuroinflammation in the psychosis and cognitive deficitsinduced by repeated low doses of MA. This review providesa comprehensive description of pertinent findingsfrom human and animal studies, with an emphasis on thecurrent understanding of the underlying mechanisms ofMA neuropsychotoxicity and its relevance to Parkinson’sdisease or schizophrenia.

참고문헌 (Reference)

• 1 Hirata H, "p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies" 69 : 780-790, 1997
• 2 Jin H, "a-Synuclein negatively regulates protein kinase Cd expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity" 31 : 2035-2051, 2011
• 3 Ajjimaporn A, "Zinc rescues dopaminergic SK-N-SH cell lines from methamphetamine-induced toxicity" 77 : 361-366, 2008
• 4 United Nations Office on Drugs and Crime, "World Drug Report 2015" United Nations
• 5 Moszczynska A, "Why is Parkinsonism not a feature of human methamphetamine users?" 127 : 363-370, 2004
• 6 Kaul S, "Tyrosine phosphorylation regulates the proteolytic activation of protein kinase Cdelta in dopaminergic neuronal cells" 280 : 28721-28730, 2005
• 7 Sonsalla PK, "Treatment of mice with methamphetamine produces cell loss in the substantia nigra" 738 : 172-175, 1996
• 8 Seddigh R, "Treating methamphetamine-induced resistant psychosis with clozapine" 2014 : 845145-, 2014
• 9 Jin H, "Transcriptional regulation of pro-apoptotic protein kinase Cdelta: implications for oxidative stress-induced neuronal cell death" 286 : 19840-19859, 2011
• 10 Speidel D, "Transcription-independent p53 apoptosis: an alternative route to death" 20 : 14-24, 2010
• 11 Walker J, "Total antioxidant capacity is significantly lower in cocaine-dependent and methamphetamine-dependent patients relative to normal controls: results from a preliminary study" 29 : 537-543, 2014
• 12 Johnson-Davis KL, "The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity" 482 : 151-154, 2003
• 13 Itzhak Y, "The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo" 67 : 1770-1773, 1996
• 14 Remington G, "The neurobiology of relapse in schizophrenia" 152 : 381-390, 2014
• 15 Hsieh JH, "The neurobiology of methamphetamine induced psychosis" 8 : 537-, 2014
• 16 Barr AM, "The need for speed: an update on methamphetamine addiction" 31 : 301-313, 2006
• 17 Hastrup H, "The human dopamine transporter forms a tetramer in the plasma membrane: crosslinking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs" 278 : 45045-45048, 2003
• 18 Eichenbaum H, "The hippocampus and declarative memory:cognitive mechanisms and neural codes" 127 : 199-207, 2001
• 19 Heysieattalab S, "The effects of GABAA and NMDA receptors in the shell-accumbens on spatial memory of METHtreated rats" 142 : 23-35, 2016
• 20 Simon SL, "The effect of relapse on cognition in abstinent methamphetamine abusers" 27 : 59-66, 2004
• 21 Yamada H, "The dopamine D1 receptor agonist, but not the D2 receptor agonist, induces gene expression of Homer 1a in rat striatum and nucleus accumbens" 1131 : 88-96, 2007
• 22 Peter D, "The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors" 269 : 7231-7237, 1994
• 23 Harris AC, "The anti-(?)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (?)-methamphetamine effects on intracranial self-stimulation in rats" 10 : e0118787-, 2015
• 24 Pakkenberg B, "The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method" 54 : 30-33, 1991
• 25 Sucic S, "The N terminus of monoamine transporters is a lever required for the action of amphetamines" 285 : 10924-10938, 2010
• 26 Chen YJ, "Tetrahydropalmatine protects against methamphetamine-induced spatial learning and memory impairment in mice" 28 : 222-232, 2012
• 27 Damghani F, "Swimming exercise attenuates psychological dependence and voluntary methamphetamine consumption in methamphetamine withdrawn rats" 19 : 594-600, 2016
• 28 Yui K, "Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis" 914 : 292-302, 2000
• 29 Castino R, "Suppression of autophagy precipitates neuronal cell death following low doses of methamphetamine" 106 : 1426-1439, 2008
• 30 Stephans SE, "Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum" 71 : 613-621, 1998
• 31 Wang Q, "Subpicomolar diphenyleneiodonium inhibits microglial NADPH oxidase with high specificity and shows great potential as a therapeutic agent for neurodegenerative diseases" 62 : 2034-2043, 2014
• 32 Yui K, "Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia" 914 : 1-12, 2000
• 33 Thompson PM, "Structural abnormalities in the brains of human subjects who use methamphetamine" 24 : 6028-6036, 2004
• 34 Eisch AJ, "Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine" 598 : 321-326, 1992
• 35 Wilson JM, "Striatal dopamine nerve terminal markers in human, chronic methamphetamine users" 2 : 699-703, 1996
• 36 Gross NB, "Striatal dopamine D1 and D2receptors: widespread influences on methamphetamine-induced dopamine and serotonin neurotoxicity" 65 : 1144-1155, 2011
• 37 Yui K, "Stress induced spontaneous recurrence of methamphetamine psychosis: the relation between stressful experiences and sensitivity to stress" 58 : 67-75, 2000
• 38 Ujike H, "Stimulant-induced psychosis and schizophrenia: the role of sensitization" 4 : 177-184, 2002
• 39 Dai H, "Social isolation stress significantly enhanced the disruption of prepulse inhibition in mice repeatedly treated with methamphetamine" 1025 : 257-266, 2004
• 40 Lu P, "Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment" 207 : 387-393, 2010
• 41 Morgan ME, "Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extrastriatal dopaminergic nuclei" 19 : 989-995, 1980
• 42 Bisagno V, "Short toxic methamphetamine schedule impairs object recognition task in male rats" 940 : 95-101, 2002
• 43 Reichel CM, "Sex differences in escalation of methamphetamine self-administration: cognitive and motivational consequences in rats" 223 : 371-380, 2012
• 44 Imam SZ, "Selenium, an antioxidant, protects against methamphetamineinduced dopaminergic neurotoxicity" 818 : 575-578, 1999
• 45 Imam SZ, "Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic toxicity and peroxynitrite generation" 855 : 186-191, 2000
• 46 Kim HC, "Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss;comparison with MPTP model" 862 : 247-252, 2000
• 47 Granado N, "Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine" 18 : 48-58, 2010
• 48 Kaneko Y, "Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine" 32 : 658-664, 2007
• 49 Battaglia G, "Selective blockade of mGlu5metabotropic glutamate receptors is protective against methamphetamine neurotoxicity" 22 : 2135-2141, 2002
• 50 Wu XF, "S-Nitrosylating protein disulphide isomerase mediates a-synuclein aggregation caused by methamphetamine exposure in PC12 cells" 230 : 19-27, 2014
• 51 Seemann S, "Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity" 24 : 3853-3863, 2005
• 52 Shimazoe T, "Roles of adenosine A(1) and A(2A) receptors in the expression and development of methamphetamine-induced sensitization" 388 : 249-254, 2000
• 53 Sonsalla PK, "Roles of D1 and D2dopamine receptor subtypes in mediating the methamphetamineinduced changes in monoamine systems" 238 : 932-937, 1986
• 54 Nakajima A, "Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity" 24 : 2212-2225, 2004
• 55 Kanthasamy AG, "Role of proteolytic activation of protein kinase Cdelta in oxidative stress-induced apoptosis" 5 : 609-620, 2003
• 56 Shin EJ, "Role of oxidative stress in methamphetamineinduced dopaminergic toxicity mediated by protein kinase Cd" 232 : 98-113, 2012
• 57 Di Monte DA, "Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase" 67 : 2443-2450, 1996
• 58 Shin EJ, "Role of microsomal epoxide hydrolase in methamphetamine-induced drug dependence in mice" 87 : 3679-3686, 2009
• 59 Fumagalli F, "Role of dopamine transporter in methamphetamine-induced neurotoxicity:evidence frommice lacking the transporter" 18 : 4861-4869, 1998
• 60 Clemens KJ, "Repeated weekly exposure to MDMA, methamphetamine or their combination:long-term behavioural and neurochemical effects in rats" 86 : 183-190, 2007
• 61 Nagai T, "Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol" 194 : 21-32, 2007
• 62 Kamei H, "Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice" 59 : 75-84, 2006
• 63 O’Dell SJ, "Repeated administration of methamphetamine damages cells in the somatosensory cortex: overlap with cytochrome oxidase-rich barrels" 37 : 32-37, 2000
• 64 Brodie C, "Regulation of cell apoptosis by protein kinase c delta" 8 : 19-27, 2003
• 65 Tsuji T, "Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen" 34 : 764-774, 2009
• 66 Guillot TS, "Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis" 106 : 2205-2217, 2008
• 67 Frey K, "Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine" 334 : 273-279, 1997
• 68 McCann UD, "Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users:evidence from positron emission tomography studies with [11C]WIN-35,428" 18 : 8417-8422, 1998
• 69 Schultz CC, "Reduced cortical thickness is associated with the glutamatergic regulatory gene risk variant DAOA Arg30Lys in schizophrenia" 36 : 1747-1753, 2011
• 70 Melega WP, "Recovery of striatal dopamine function after acute amphetamine-and METH-induced neurotoxicity in the vervet monkey" 766 : 113-120, 1997
• 71 Cass WA, "Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine" 19 : 7653-7660, 1999
• 72 Harvey DC, "Recovery from methamphetamine induced long-term nigrostriatal dopaminergicdeficits without substantia nigra cell loss" 871 : 259-270, 2000
• 73 Whitehead RE, "Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter" 76 : 1242-1251, 2001
• 74 Srisurapanont M, "Psychotic symptoms in methamphetamine psychotic inpatients" 6 : 347-352, 2003
• 75 Cervinski MA, "Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms" 280 : 40442-40449, 2005
• 76 Lieberman JA, "Provocative tests with psychostimulant drugs in schizophrenia" 91 : 415-433, 1987
• 77 Gordon R, "Protein kinase Cd upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson’s disease" 93 : 96-114, 2016
• 78 Hashimoto K, "Protective effects on N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine" 29 : 2018-2023, 2004
• 79 Chen H, "Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine" 222 : 37-45, 2012
• 80 Wu CF, "Protective effects of pseudoginsenoside-F11 on methamphetamine-induced neurotoxicity in mice" 76 : 103-109, 2003
• 81 Hashimoto K, "Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys" 61 : 577-581, 2007
• 82 Zhang L, "Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine" 30 : 1381-1393, 2006
• 83 Hozumi H, "Protective effects of interferon-gamma against methamphetamine-induced neurotoxicity" 177 : 123-129, 2008
• 84 Kim HC, "Protection of methamphetamine nigrostriatal toxicity by dietary selenium" 851 : 76-86, 1999
• 85 Rendell PG, "Prospective memory impairment in former users of methamphetamine" 203 : 609-616, 2009
• 86 Segal DS, "Prolonged exposure of rats to intravenous methamphetamine:behavioral and neurochemical characterization" 180 : 501-512, 2005
• 87 Lecomte T, "Profiles of individuals seeking psychiatric help for psychotic symptoms linked to methamphetamine abuse—baseline results from the MAPS (methamphetamine and psychosis study)" 3 : 168-181, 2010
• 88 Henry BL, "Prepulse inhibition in HIV-1 gp120transgenic mice after withdrawal from chronic methamphetamine" 25 : 12-22, 2014
• 89 Lominac KD, "Prefrontal glutamate correlates of methamphetamine sensitization and preference" 43 : 689-702, 2016
• 90 Chen CK, "Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis" 33 : 1407-1414, 2003
• 91 Jung BD, "Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration" 56 : 229-244, 2010
• 92 Wang Q, "Post-treatment with ultralow dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson’s disease models" 138 : 1247-1262, 2015
• 93 Bowyer JF, "Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation" 919 : 179-183, 2001
• 94 Grace AA, "Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia" 41 : 1-24, 1991
• 95 Hyoung-Chun Kim, "Pharmacological Action of Panax Ginseng on the Behavioral Toxicities Induced by Psychotropic Agents" 대한약학회 28 (28): 995-1001, 2005
• 96 McCann UD, "Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users" 62 : 91-100, 2008
• 97 Baumann MH, "Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate" 301 : 1190-1197, 2002
• 98 Son JH, "Perseverative behavior in rats with methamphetamine-induced neurotoxicity" 67 : 95-103, 2013
• 99 Imam SZ, "Peroxynitrite plays a role in methamphetamineinduced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase" 76 : 745-749, 2001
• 100 Park SU, "Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons" 22 : 4399-4405, 2002
• 101 Yoshida K, "PKCdelta signaling: mechanisms of DNA damage response and apoptosis" 19 : 892-901, 2007
• 102 Shin EJ, "PKCd inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment" 59 : 39-50, 2011
• 103 Tran TV, "PKCd gene facilitates cognitive impairment induced by low doses of methamphetamine (MA) in mice" 19 (19): 50-, 2016
• 104 Di Giacomo V, "PKC-d signalling pathway is involved in H9c2cells differentiation" 80 : 204-212, 2010
• 105 Huang MC, "Oxidative stress status in recently abstinent methamphetamine abusers" 67 : 92-100, 2013
• 106 Solhi H, "Oxidative stress and lipid peroxidation in prolonged users of methamphetamine" 7 : 79-82, 2014
• 107 Cunha-Oliveira T, "Oxidative stress and drugs of abuse: an update" 10 : 321-334, 2013
• 108 Winyard PG, "Oxidative activation of antioxidant defence" 30 : 453-461, 2005
• 109 Abekawa T, "Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex" 101 : 84-94, 2008
• 110 Fornai F, "Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice" 65 : 405-413, 2005
• 111 Granado N, "Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum" 59 : 1850-1863, 2011
• 112 Ohno M, "Nitric oxide synthase inhibitors block behavioral sensitization to methamphetamine in mice" 275 : 39-44, 1995
• 113 Mizoguchi H, "Nicotine ameliorates impairment of working memory in methamphetamine-treated rats" 220 : 159-163, 2011
• 114 O’Callaghan JP, "Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse" 270 : 741-751, 1994
• 115 Seiden LS, "Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections" 537 : 161-172, 1988
• 116 Schro¨der N, "Neurotoxic methamphetamine regimen severely impairs recognition memory in rats" 49 : 89-96, 2003
• 117 Thrash B, "Neurotoxic effects of methamphetamine" 35 : 171-179, 2010
• 118 Nordahl TE, "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition:a review" 15 : 317-325, 2003
• 119 Kanthasamy K, "Neuroprotective effect of resveratrol against methamphetamine-induced dopaminergic apoptotic cell death in a cell culture model of neurotoxicity" 9 : 49-53, 2011
• 120 Golembiowska K, "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats" 45 : 484-492, 2003
• 121 Rusyniak DE, "Neurologic manifestations of chronic methamphetamine abuse" 36 : 261-275, 2013
• 122 Yui K, "Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization" 4 : 512-523, 1999
• 123 Gao HM, "NADPH oxidases: novel therapeutic targets for neurodegenerative diseases" 33 : 295-303, 2012
• 124 Qin L, "NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia" 279 : 1415-1421, 2004
• 125 Qin L, "NADPH oxidase and aging drive microglial activaton, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration" 61 : 855-868, 2013
• 126 Torres B, "N-terminus regulation of VMAT2mediates methamphetamine-stimulated efflux" 259 : 194-202, 2014
• 127 Khoshbouei H, "N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux" 2 : E78-, 2004
• 128 Shin EJ, "N-methyl, N-propynyl-2-phenylethylamine (MPPE), a selegiline analog, attenuates MPTP-induced dopaminergic toxicity with guaranteed behavioral safety: involvement of inhibitions of mitochondrial oxidative burdens and p53 gene-elicited pro-apoptotic change" 53 : 6251-6269, 2016
• 129 Zhang X, "N-acetylcysteine amide protects against methamphetamine-induced tissue damage in CD-1 mice" 31 : 931-944, 2012
• 130 Chen CK, "Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis" 136B : 87-91, 2005
• 131 Gonza´lez B, "Modafinil improves methamphetamine-induced object recognition deficits and restores prefrontal cortex ERK signaling in mice" 87 : 188-197, 2014
• 132 Raineri M, "Modafinil abrogates methamphetamine-induced neuroinflammation and apoptotic effects in the mouse striatum" 7 : e46599-, 2012
• 133 Endo H, "Mitochondrial translocation of p53 mediates release of cytochrome c and hippocampal CA1 neuronal death after transient global cerebral ischemia in rats" 26 : 7974-7983, 2006
• 134 Kroemer G, "Mitochondrial membrane permeabilization in cell death" 87 : 99-163, 2007
• 135 Barbosa DJ, "Mitochondria: key players in the neurotoxic effects of amphetamines" 89 : 1695-1725, 2015
• 136 Boger HA, "Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice" 33 : 459-466, 2009
• 137 Sriram K, "Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha" 96 : 706-718, 2006
• 138 Zhang W, "Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha synuclein" 55 : 1178-1188, 2007
• 139 Kreutzberg GW, "Microglia: a sensor for pathological events in the CNS" 19 : 312-318, 1996
• 140 Lieberman JA, "Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia" 11 : 107-118, 1994
• 141 Lee KW, "Methamphetaminesensitized mice are accompanied by memory impairment and reduction of N-methyl-D-aspartate receptor ligand binding in the prefrontal cortex and hippocampus" 178 : 101-107, 2011
• 142 Gonc¸alves J, "Methamphetamineinduced early increase of IL-6 and TNF-alpha mRNA expression in the mouse brain" 1139 : 103-111, 2008
• 143 Thrash-Williams B, "Methamphetamineinduced dopaminergic toxicity prevented owing to the neuroprotective effects of salicylic acid" 154 : 24-29, 2016
• 144 Curtin K, "Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment" 146 : 30-38, 2015
• 145 Sekine Y, "Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET" 158 : 1206-1214, 2001
• 146 Braren SH, "Methamphetamine-induced short-term increase and long-term decrease in spatial working memory affects protein Kinase M zeta (PKMf), dopamine, and glutamate receptors" 8 : 438-, 2014
• 147 Hirata H, "Methamphetamine-induced serotonin neurotoxicity is attenuated in p53-knockout mice" 768 : 345-348, 1997
• 148 Metzger RR, "Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia" 295 : 1077-1085, 2000
• 149 Lau JWS, "Methamphetamine-induced oxidative stress in cultured mouse astrocytes" 914 : 146-156, 2000
• 150 Lin M, "Methamphetamine-induced neurotoxicity linked to ubiquitinproteasome system dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in dopaminergic neuronal cells" 210 : 308-332, 2012
• 151 Ladenheim B, "Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6" 58 : 1247-1256, 2000
• 152 Asanuma M, "Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug" 352 : 13-16, 2003
• 153 De Vito MJ, "Methamphetamine-induced neuronal damage: a possible role for free radicals" 28 : 1145-1150, 1989
• 154 Asanuma M, "Methamphetamine-induced increase in striatal p53 DNA-binding activity is attenuated in Cu, Zn-superoxide dismutase transgenic mice" 325 : 191-194, 2002
• 155 Imam SZ, "Methamphetamine-induced dopaminergic neurotoxicity and production of peroxynitrite are potentiated in nerve growth factor differentiated pheochromocytoma 12 cells" 965 : 204-213, 2002
• 156 Guilarte TR, "Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity" 122 : 499-513, 2003
• 157 Reichel CM, "Methamphetamine-induced changes in the object recognition memory circuit" 62 : 1119-1126, 2012
• 158 Zhu JP, "Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice" 140 : 607-622, 2006
• 159 Deng X, "Methamphetamine-induced apoptosis is attenuated in the striata of copper-zinc superoxide dismutase transgenic mice" 83 : 121-124, 2000
• 160 Imam SZ, "Methamphetamine-induced alteration in striatal p53 and bcl-2expressions in mice" 91 : 174-178, 2001
• 161 Flora G, "Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation" 2 : 71-85, 2002
• 162 Grant KM, "Methamphetamine-associated psychosis" 7 : 113-139, 2012
• 163 Panenka WJ, "Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings" 129 : 167-179, 2013
• 164 Callaghan RC, "Methamphetamine use and schizophrenia: a population-based cohort study in California" 169 : 389-396, 2012
• 165 Maragos WF, "Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase" 878 : 218-222, 2000
• 166 Kousik SM, "Methamphetamine selfadministration results in persistent dopaminergic pathology:implications for Parkinson’s disease risk and reward-seeking" 40 : 2707-2714, 2014
• 167 McFadden LM, "Methamphetamine selfadministration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure" 340 : 295-303, 2012
• 168 Krasnova IN, "Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat" 5 : e8790-, 2010
• 169 Glasner-Edwards S, "Methamphetamine psychosis:epidemiology and management" 28 : 1115-1126, 2014
• 170 Eisch AJ, "Methamphetamine neurotoxicity:dissociation of striatal dopamine terminal damage from parietal cortical cell body injury" 30 : 433-445, 1998
• 171 Davidson C, "Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment" 36 : 1-22, 2001
• 172 Cubells JF, "Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress" 14 : 2260-2271, 1994
• 173 Thomas DM, "Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation" 311 : 1-7, 2004
• 174 Belcher AM, "Methamphetamine influences on recognition memory: comparison of escalating and single-day dosing regimens" 33 : 1453-1463, 2008
• 175 Marshall JF, "Methamphetamine influences on brain and behavior: unsafe at any speed?" 35 : 536-545, 2012
• 176 Jayanthi S, "Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades" 18 : 238-251, 2004
• 177 Baucum AJ 2nd, "Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism" 24 : 3436-3443, 2004
• 178 Nair MP, "Methamphetamine enhances HIV-1 infectivity in monocyte derived dendritic cells" 4 : 129-139, 2009
• 179 Liang H, "Methamphetamine enhances HIV infection of macrophages" 172 : 1617-1624, 2008
• 180 Kalechstein AD, "Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence" 15 : 215-220, 2003
• 181 Simon SL, "Methamphetamine dependence and neuropsychological functioning:evaluating change during early abstinence" 71 : 335-344, 2010
• 182 Deng X, "Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method" 93 : 64-69, 2001
• 183 Sekine Y, "Methamphetamine causes microglial activation in the brains of human abusers" 28 : 5756-5761, 2008
• 184 Ac¸ikgo¨z O, "Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum" 813 : 200-202, 1998
• 185 Jayanthi S, "Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex" 15 : 1745-1752, 2001
• 186 Ares-Santos S, "Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining" 39 : 1066-1080, 2014
• 187 Burrows KB, "Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex" 27 : 133-144, 1997
• 188 Mahajan SD, "Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: implication for HIV-1neuropathogenesis in the context of drug abuse" 1203 : 133-148, 2008
• 189 Chipana C, "Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents" 54 : 1254-1263, 2008
• 190 Wu J, "Melatonin treatment during the incubation of sensitization attenuates methamphetamine-induced locomotor sensitization and MeCP2 expression" 65 : 145-152, 2016
• 191 Hirata H, "Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain" 30 : 150-155, 1998
• 192 Hirsch E, "Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease" 334 : 345-348, 1988
• 193 Sulzer D, "Mechanisms of neurotransmitter release by amphetamines: a review" 75 : 406-433, 2005
• 194 Riddle EL, "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity" 8 : E413-E418, 2006
• 195 Dluzen DE, "Markers associated with sex differences in methamphetamine-induced striatal dopamine neurotoxicity" 9 : 40-44, 2011
• 196 Darke S, "Major physical and psychological harms of methamphetamine use" 27 : 253-262, 2008
• 197 Thomas DM, "MK-801 and dextromethorphan block microglial activation and protect against methamphetamineinduced neurotoxicity" 1050 : 190-198, 2005
• 198 Adams JP, "MAPK regulation of gene expression in the central nervous system" 60 : 377-394, 2000
• 199 Volkow ND, "Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex" 158 : 2015-2021, 2001
• 200 Reichel CM, "Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5" 36 : 782-792, 2011
• 201 Volkow ND, "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence" 21 : 9414-9418, 2001
• 202 Akiyama K, "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence" 1074 : 125-134, 2006
• 203 Hodges AB, "Long-term protective effects of methamphetamine preconditioning against single-day methamphetamine toxic challenges" 9 : 35-39, 2011
• 204 Melega WP, "Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles" 33 : 1441-1452, 2008
• 205 Chiu HY, "Long-lasting alterations in 5-HT2A receptor after a binge regimen of methamphetamine in mice" 17 : 1647-1658, 2014
• 206 Hotchkiss AJ, "Long term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain" 214 : 257-262, 1980
• 207 Nguyen XK, "Liposomal melatonin rescues methamphetamine-elicited mitochondrial burdens, pro-apoptosis, and dopaminergic degeneration through the inhibition PKCd gene" 58 : 86-106, 2015
• 208 Fitzmaurice PS, "Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine" 319 : 703-709, 2006
• 209 Nakato Y, "Lamotrigine blocks the initiation and expression of repeated high-dose methamphetamine-induced prepulse inhibition deficit in rats" 481 : 183-187, 2010
• 210 Miyamoto Y, "Knockdown of dopamine D2 receptors in the nucleus accumbens core suppresses methamphetamine-induced behaviors and signal transduction in mice" 18 : pyu038-, 2014
• 211 Friend DM, "Is there a role for nitric oxide in methamphetamine-induced dopamine terminal degeneration?" 25 : 153-160, 2014
• 212 Arai S, "Involvement of pallidotegmental neurons in methamphetamine- and MK-801-induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABAB receptor agonist baclofen" 33 : 3164-3175, 2008
• 213 Beauvais G, "Involvement of dopamine receptors in binge methamphetamineinduced activation of endoplasmic reticulum and mitochondrial stress pathways" 6 : e28946-, 2011
• 214 Saha K, "Intracellular methamphetamine prevents the dopamine-induced enhancement of neuronal firing" 289 : 22246-22257, 2014
• 215 Dang DK, "Inhibition of protein kinase (PK) Cd attenuates methamphetamine-induced dopaminergic toxicity via upregulation of phosphorylation of tyrosine hydroxylase at Ser40 by modulation of protein phosphatase 2A and PKA" 42 : 192-201, 2015
• 216 Xu W, "Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors" 58 : 110-121, 2005
• 217 Boileau I, "Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker?" 28 : 9850-9856, 2008
• 218 Callaghan RC, "Increased risk of Parkinson’s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs" 120 : 35-40, 2012
• 219 Fumagalli F, "Increased METH neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice" 19 : 2424-2431, 1999
• 220 Callaghan RC, "Incidence of Parkinson’s disease among hospital patients with methamphetamine-use disorders" 25 : 2333-2339, 2010
• 221 Shiba T, "In vivo imaging of mitochondrial function in methamphetamine-treated rats" 57 : 866-872, 2011
• 222 Jiang J, "In vivo effects of methamphetamine on HIV-1 replication: a population-based study" 159 : 246-254, 2016
• 223 Mizoguchi H, "Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice" 196 : 233-241, 2008
• 224 Belcher AM, "Impaired object recognition memory following methamphetamine, but not pchloroamphetamine-or d-amphetamine-induced neurotoxicity" 30 : 2026-2034, 2005
• 225 Salamanca SA, "Impact of methamphetamine on infection and immunity" 8 : 445-, 2015
• 226 Kigerl KA, "Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord" 29 : 13435-13444, 2009
• 227 Cen X, "Identification of Piccolo as a regulator of behavioral plasticity and dopamine transporter internalization" 13 : 451-463, 2008
• 228 Huang CL, "Hydrogen peroxide induces loss of dopamine transporter activity: a calcium-dependent oxidative mechanism" 86 : 1247-1259, 2003
• 229 Theodore S, "Human immunodeficiency virus-1 protein tat and methamphetamine interactions" 1074 : 178-190, 2006
• 230 Maragos WF, "Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function" 83 : 955-963, 2002
• 231 Anglin MD, "History of the methamphetamine problem" 32 : 137-141, 2000
• 232 Mark KA, "High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity" 24 : 11449-11456, 2004
• 233 Motbey CP, "High levels of intravenous mephedrone (4-methylmethcathinone)self-administration in rats: neural consequences and comparison with methamphetamine" 27 : 823-836, 2013
• 234 Borgmann K, "HIV-1, methamphetamine and astrocytes at neuroinflammatory Crossroads" 6 : 1143-, 2015
• 235 Cass WA, "HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat" 984 : 133-142, 2003
• 236 Shin EJ, "Ginsenosides attenuate methamphetamine-induced behavioral side effects in mice via activation of adenosine A2A receptors: possible involvements of the striatal reduction in AP-1 DNA binding activity and proenkephalin gene expression" 158 : 143-157, 2005
• 237 Shin EJ, "Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cd gene" 49 : 1400-1421, 2014
• 238 Nam Y, "Ginsenoside Re protects methamphetamine-induced mitochondrial burdens and proapoptosis via genetic inhibition of protein kinase C d in human neuroblastoma dopaminergic SH-SY5Y cell lines" 35 : 927-944, 2015
• 239 Chanasong R, "Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population" 551 : 58-61, 2013
• 240 Okochi T, "Genetic association analysis of NOS3 and methamphetamine-induced psychosis among Japanese" 9 : 151-154, 2011
• 241 Okumura T, "Genetic association analysis of NOS1 and methamphetamineinduced psychosis among Japanese" 9 : 155-159, 2011
• 242 Noda Y, "Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems" 13 : 1343-1354, 2010
• 243 Panicker N, "Fyn kinase regulates microglial neuroinflammatory responses in cell culture and animal models of Parkinson’s Disease" 35 : 10058-10077, 2015
• 244 Bowyer JF, "Further studies of the role of hyperthermia in methamphetamine neurotoxicity" 268 : 1571-1580, 1994
• 245 Pirompul N, "Farnesyltransferase inhibitor attenuates methamphetamine toxicity-induced Ras proteins activation and cell death in neuroblastoma SHSY5Y cells" 545 : 138-143, 2013
• 246 Scofield MD, "Failure to recognize novelty after extended methamphetamine self-administration results from loss of long-term depression in the perirhinal cortex" 40 : 2526-2535, 2015
• 247 Schwendt M, "Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion" 331 : 555-562, 2009
• 248 Rogers JL, "Extended methamphetamine self-administration enhances reinstatement of drug seeking and impairs novel object recognition in rats" 199 : 615-624, 2008
• 249 Hadamitzky M, "Extended access to methamphetamine self-administration affects sensorimotor gating in rats" 217 : 386-390, 2011
• 250 Kim YH, "Expression of cyclin D3 through Sp1 sites by histone deacetylase inhibitors is mediated with protein kinase C-delta (PKC-delta) signal pathway" 101 : 987-995, 2007
• 251 Ernst T, "Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study" 54 : 1344-1349, 2000
• 252 Kuczenski R, "Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat" 207 : 42-51, 2007
• 253 Segal DS, "Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge" 28 : 1730-1740, 2003
• 254 Saminathan H, "Environmental neurotoxic pesticide dieldrin activates a non receptor tyrosine kinase to promote PKCd-mediated dopaminergic apoptosis in a dopaminergic neuronal cell model" 32 : 567-577, 2011
• 255 Berg D, "Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons" 68 (68): 932-937, 2011
• 256 Wu CW, "Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SHSY5Y cells during methamphetamine induced apoptosis" 220 : 243-251, 2007
• 257 Wang Q, "Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice" 9 : 124-, 2012
• 258 Althobaiti YS, "Effects of repeated high-dose methamphetamine and ceftriaxone post-treatments on tissue content of dopamine and serotonin as well as glutamate and glutamine" 634 : 25-31, 2016
• 259 Chao YL, "Effects of repeated electroconvulsive shock on methamphetamine-induced behavioral abnormalities in mice" 5 : 393-401, 2012
• 260 Abekawa T, "Effects of nitric oxide (NO)synthesis inhibition on the development of supersensitivity to stereotypy and locomotion stimulating effects of methamphetamine" 679 : 200-204, 1995
• 261 Kuribara H, "Effects of dopamine antagonism on methamphetamine sensitization: evaluation by ambulatory activity in mice" 47 : 101-106, 1994
• 262 Sams-Dodd F, "Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats" 19 : 18-25, 1998
• 263 Abekawa T, "Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents" 125 : 77-87, 2011
• 264 Yoshimatsu A, "Effects of adenosine A1- and A2A-receptor agonists on enhancement of dopamine release from the striatum in methamphetamine-sensitized rats" 86 : 254-257, 2001
• 265 Pu C, "Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex" 23 : 328-334, 1996
• 266 Itzhak Y, "Effect of melatonin on methamphetamine-and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioral sensitization" 37 : 781-791, 1998
• 267 Racay P, "Effect of ischemic preconditioning on mitochondrial dysfunction and mitochondrial p53 translocation after transient global cerebral ischemia in rats" 32 : 1823-1832, 2007
• 268 Fukami G, "Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine" 1016 : 90-95, 2004
• 269 Iijima M, "Effect of an mGlu2/3 receptor antagonist on depressive behavior induced by withdrawal from chronic treatment with methamphetamine" 246 : 24-28, 2013
• 270 Park MJ, "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity" 1109 : 176-182, 2006
• 271 Grace CE, "Effect of a neurotoxic dose regimen of (?)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6mice" 32 : 346-355, 2010
• 272 Herring NR, "Effect of (?)-methamphetamine on path integration learning, novel object recognition, and neurotoxicity in rats" 199 : 637-650, 2008
• 273 Latchoumycandane C, "Dopaminergic neurotoxicant 6-OHDA induces oxidative damage through proteolytic activation of PKCd in cell culture and animal models of Parkinson’s disease" 256 : 314-323, 2011
• 274 Kuhn DM, "Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage" 1074 : 31-41, 2006
• 275 LaVoie MJ, "Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine" 19 : 1484-1491, 1999
• 276 Granado N, "Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA" 42 : 391-403, 2011
• 277 Kuribara H, "Dopamine D1 receptor antagonist SCH 23390retards methamphetamine sensitization in both combined administration and early posttreatment schedules in mice" 52 : 759-763, 1995
• 278 Ares-Santos S, "Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine" 45 : 810-820, 2012
• 279 Nakagawa Y, "Diversity and plasticity of microglial cells in psychiatric and neurological disorders" 154 : 21-35, 2015
• 280 Pucilowska J, "Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuro-cardio-facialcutaneous and related syndromes" 32 : 8663-8677, 2012
• 281 Kai N, "Differential roles of dopamine D1 and D2 receptor-containing neurons of the nucleus accumbens shell in behavioral sensitization" 135 : 1232-1241, 2015
• 282 Itzhak Y, "Differential response of nNOS knockout mice to MDMA (‘‘ecstasy’’)- and methamphetamineinduced psychomotor sensitization and neurotoxicity" 1025 : 119-128, 2004
• 283 Brown JM, "Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression" 98 : 495-505, 2006
• 284 Ango F, "Dendritic and axonal targeting of type 5 metabotropic glutamate receptor is regulated by homer1 proteins and neuronal excitation" 20 : 8710-8716, 2000
• 285 Hayashi T, "Delta opioid peptide [D-Ala2, D-Leu5]enkephalin causes a near complete blockade of the neuronal damage caused by a single high dose of methamphetamine: examining the role of p53" 39 : 305-312, 2001
• 286 Bosse KE, "Deficits in behavioral sensitization and dopaminergic responses to methamphetamine in adenylyl cyclase 1/8-deficient mice" 135 : 1218-1231, 2015
• 287 Cass WA, "Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine" 280 : 105-113, 1997
• 288 Fallgatter AJ, "DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in schizophrenic patientssupport for the glutamate hypothesis of schizophrenias" 9 : 489-497, 2010
• 289 Kita T, "Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption" 92 : 178-195, 2003
• 290 Gao HM, "Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease" 17 : 1954-1956, 2003
• 291 Mizuno M, "Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period" 1025 : 612-618, 2004
• 292 Sonsalla PK, "Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice" 256 : 506-512, 1991
• 293 Itzhak Y, "Comparison between the role of the neuronal and inducible nitric oxide synthase in methamphetamine-induced neurotoxicity and sensitization" 914 : 104-111, 2000
• 294 Bachmann RF, "Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamineinduced mitochondrial damage" 12 : 805-822, 2009
• 295 Simon SL, "Cognitive performance of current methamphetamine and cocaine abusers" 21 : 61-74, 2002
• 296 Simon SL, "Cognitive impairment in individuals currently using methamphetamine" 9 : 222-231, 2000
• 297 Johanson CE, "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers" 185 : 327-338, 2006
• 298 Zarrabi H, "Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients" 16 : 44-, 2016
• 299 Ujike H, "Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis" 1025 : 279-287, 2004
• 300 Kalayasiri R, "Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C? T in a Thai treatment cohort" 109 : 965-976, 2014
• 301 Tata DA, "Chronic stress enhances methamphetamine-induced extracellular glutamate and excitotoxicity in the rat striatum" 62 : 325-336, 2008
• 302 Tomiyama G, "Chronic schizophrenia-like states in methamphetamine psychosis" 44 : 531-539, 1990
• 303 North A, "Chronic methamphetamine exposure produces a delayed, long-lasting memory deficit" 67 : 245-257, 2013
• 304 Fischer JF, "Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model" 208 : 203-209, 1979
• 305 Eisch AJ, "Characterizing cortical neuron injury with Fluoro-Jade labeling after a neurotoxic regimen of methamphetamine" 30 : 329-333, 1998
• 306 McConnell SE, "Characterization of binge-dosed methamphetamine-induced neurotoxicity and neuroinflammation" 50 : 131-141, 2015
• 307 Burrows KB, "Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines" 292 : 853-860, 2000
• 308 Kaul S, "Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP?)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration" 18 : 1387-1401, 2003
• 309 Koriem KM, "Caffeic acid protects tissue antioxidants and DNA content in methamphetamine induced tissue toxicity in Sprague Dawley rats" 23 : 134-143, 2013
• 310 Krasnova IN, "CREB phosphorylation regulates striatal transcriptional responses in the self-administration model of methamphetamine addiction in the rat" 58 : 132-143, 2013
• 311 Kish SJ, "Brain serotonin transporter in human methamphetamine users" 202 : 649-661, 2009
• 312 Sekine Y, "Brain serotonin transporter density and aggression in abstinent methamphetamine abusers" 63 : 90-100, 2006
• 313 Villemagne V, "Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428positron emission tomography studies and direct in vitro determinations" 18 : 419-427, 1998
• 314 Mirecki A, "Brain antioxidant systems in human methamphetamine users" 8 : 1396-1408, 2004
• 315 Paulus MP, "Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects" 26 : 53-63, 2002
• 316 Wu PH, "Baicalein attenuates methamphetamine-induced loss of dopamine transporter in mouse striatum" 226 : 238-245, 2006
• 317 Ren Q, "BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms" 5 : e666-, 2015
• 318 Manning EE, "BDNF deficiency and youngadult methamphetamine induce sex-specific effects on prepulse inhibition regulation" 7 : 92-, 2013
• 319 Hermida-Ameijeiras A, "Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions" 45 : 103-116, 2004
• 320 Hirata H, "Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZnsuperoxide dismutase transgenic mice" 714 : 95-103, 1996
• 321 Cadet JL, "Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice" 62 : 380-383, 1994
• 322 Volkow ND, "Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers" 158 : 377-382, 2001
• 323 Newton TF, "Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers" 115 : 194-198, 2004
• 324 Nakamura K, "Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations" 120 : 243-252, 2006
• 325 Futamura T, "Aripiprazole attenuates established behavioral sensitization induced by methamphetamine" 34 : 1115-1119, 2010
• 326 Dang DK, "Apocynin prevents mitochondrial burdens, microglial activation, and pro-apoptosis induced by a toxic dose of methamphetamine in the striatum of mice via inhibition of p47phox activation by ERK" 13 : 12-, 2016
• 327 Maehara S, "Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia" 91 : 140-149, 2008
• 328 Hogan KA, "Analysis of VMAT2binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations" 74 : 2217-2220, 2000
• 329 Rosario Moratalla, "Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms" Elsevier BV 155 : 149-170, 2017
• 330 Goodwin JS, "Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo" 284 : 2978-2989, 2009
• 331 Wagner GC, "Alphamethyltyrosine attenuates and reserpine increases METH-induced neuronal changes" 270 : 285-288, 1983
• 332 Truong JG, "Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity" 314 : 1087-1092, 2005
• 333 Todd G, "Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism" 25 : 27-32, 2016
• 334 Sato M, "Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis" 18 : 429-440, 1983
• 335 Silva CD, "A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice" 25 : 295-304, 2014
• 336 Cruickshank CC, "A review of the clinical pharmacology of methamphetamine" 104 : 1085-1099, 2009
• 337 Xie Z, "A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain" 330 : 316-325, 2009
• 338 Hashimoto K, "A neurotoxic dose of methamphetamine induces gene expression of Homer 1a, but not Homer 1b or 1c, in the striatum and nucleus accumbens" 51 : 227-232, 2007
• 339 Sato M, "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis" 654 : 160-170, 1992
• 340 Takigawa M, "A dual approach to self-stimulation and locomotor trace affected by chronic methamphetamine treatment for an animal model of schizophrenia" 71 : 321-325, 1993
• 341 Fantegrossi WE, "A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse" 151 : 533-543, 2008
• 342 Ren Q, "7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine" 231 : 159-166, 2014
• 343 Roberts AC, "6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine" 14 : 2531-2544, 1994